CERENOME, INC.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

CNSY$0.68+19.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Grant revenue	$411	$1,390	$1,439	$2,449
Operating expenses:
Research and development	4,265	1,246	7,130	3,002
General and administrative	5,203	1,682	10,485	4,521
Total operating expenses	9,468	2,928	17,615	7,523
Operating loss	(9,057)	(1,538)	(16,176)	(5,074)
Other income (expense):
Interest income	56	27	246	28
Interest expense	(5)	—	(22)	(548)
Financing expenses	—	150	—	(3,061)
Warrant issuance costs	—	—	—	(964)
Change in fair value of derivative instruments	—	6,512	—	(2,631)
Total other income (expense)	51	6,689	224	(7,176)
Net income (loss)	$(9,006)	$5,151	$(15,952)	$(12,250)
Per share information
Net income (loss) per share of common stock – basic	$(1.31)	$0.62	$(2.36)	$(12.54)
Weighted average number of shares of common stock outstanding – basic	6,898,804	1,935,554	6,773,125	976,885
Net loss per share of common stock – diluted	$(1.31)	$(0.16)	$(2.36)	$(12.54)
Weighted average number of shares of common stock outstanding – diluted	6,898,804	8,366,199	6,773,125	976,885

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.